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The transcription factor PU.1 plays a crucial role during normal haematopoiesis in both myeloid cells and B-lymphocytes. Mice with a
disruption in both alleles of the PU.1 locus were found to lack macrophages and B cells and had delayed appearance of neutrophils. In
addition, critical decrease of PU.1 expression is sufficient to cause acute myeloid leukaemia (AML) and lymphomas in mice. Recently,
we reported that heterozygous mutations in the PU.1 gene are present in some patients with AML. Thus, we hypothesised that PU.1
mutations might also contribute to the development of acute leukaemias of the B-cell lineage. Here, we screened 62 patients with
B-cell acute lymphoblastic leukaemia (B-ALL) at diagnosis for genomic mutations by direct sequencing of all five exons of the PU.1
gene. We found no genomic alteration of the PU.1 gene suggesting that PU.1 mutations are not likely to be common in B-ALL.
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PU.1, a member of the ets family of transcription factors, is
upregulated during haematopoietic development, and is specifi-
cally expressed in mature myeloid and B cells (Klemsz et al, 1990;
Hromas et al, 1993; Chen et al, 1995). The crucial and exclusive
role of PU.1 in haematopoietic differentiation is established by the
following observations. A number of genes are regulated by PU.1
in both myeloid and B-cell lineages, including those encoding
colony-stimulating factor receptors and immunoglobulin subunits
(Shin and Koshland, 1993; Zhang et al, 1994; Hohaus et al, 1995;
Smith et al, 1996). Overexpression of PU.1 early in erythroid
development blocks erythroblast differentiation and induces
murine erythroleukaemia (Moreau-Gachelin et al, 1988, 1996; Paul
et al, 1991). Gene targeting of PU.1 results in the failure of
development of mature myeloid cells, and the addition of PU.1
site-containing competitor oligonucleotides to human CD34
þ
bone marrow cells inhibits in vitro myeloid colony formation
(Voso et al, 1994; Fisher et al, 1998). In addition, mice with a
disruption in both alleles of the PU.1 locus were found to have
severe defects in the development of both myeloid and lymphoid
cells, characterised by the absence of macrophages and B cells,
and the delayed appearance of neutrophils (Scott et al, 1994;
McKercher et al, 1996).
Although the role of PU.1 in normal haematopoiesis has been
broadly investigated, its significance for leukaemogenesis is less
known. Recently, it was shown that an 80% reduction of PU.1
expression is sufficient to cause acute myeloid leukaemia (AML) in
mice (Rosenbauer et al, 2004). Our group has reported that
heterozygous PU.1 mutations are observed in some AML patients
(Mueller et al, 2002). Finally, we demonstrated that PU.1
expression is critically suppressed by the PML-RARA fusion
protein, the hallmark of AML-M3 patients (Mueller et al, 2006).
These findings point to a role of PU.1 for both normal
haematopoietic differentiation and leukaemogenesis.
With regard to the finding of PU.1 mutations in some AML
patients and to the role of PU.1 in B-cell development, we
hypothesised that B-cell acute lymphoblastic leukaemia (B-ALL)
might similarly harbour genomic abnormalities in the PU.1 gene.
Therefore, we screened a collection of 62 B-ALL patients for PU.1
mutations.
PATIENTS AND METHODS
Analysis of mutations of the PU.1 gene was performed in 45
healthy volunteers (bone marrow donors) and 62 patients with
B-ALL. Forty-six childhood B-ALL patients were treated on one of
two consecutive Dana Farber Cancer Institute childhood ALL
protocols (85-001 or 87-001), and 16 adult B-ALL patients were
treated on the French Intergroup LALA 94 protocol in Bern,
Switzerland. The 46 childhood ALL patients have previously been
presented for unrelated purposes (McLean et al, 1996). Patient
characteristics are presented in Table 1. The male/female ratio was
40/22 among the ALL patients and 29/16 for the healthy volunteers,
and the age range was 1–62 years (median 9 years) for the ALL
patients and 16–78 years (median 29 years) for the control group.
The patient samples were collected at the time of diagnosis
before initiation of treatment and after having obtained informed
consent. Mononuclear cells were isolated from bone marrow
samples by Ficoll density gradient centrifugation and cryopreserved
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sin liquid nitrogen until molecular analysis. Detection of PU.1
mutations was made on genomic DNA extracted from bone
marrow samples. Polymerase chain reaction (PCR) analysis using
exon-specific primers was performed of the five PU.1 exons
comprising the entire coding region of the PU.1 gene. Exon-
specific primers were designed from the sequence in GenBank
(AC019059 and AC01841; Supplementary Table 2). All primers
were selected to include the exon/intron boundaries to exclude
splice junction mutations. Analysis of the PCR products was
described previously (Mueller et al, 2002). Briefly, PCR products
were electrophoresed on 1% agarose gels, gel-purified (Qiagen,
Valentia, CA, USA), and sequenced using BigDye Terminators and
AmpliTaq FS (Applied Biosystems, Foster City, CA, USA).
RESULTS AND DISCUSSION
We screened leukaemic cells from patients with B-cell ALL
for mutations in the coding region of the PU.1 gene by
direct sequencing of exon-specific PCR products. We
observed no sequence variants in the coding sequence in
62 ALL patients (90% upper confidence bound of 3.64%)
and in 45 healthy volunteers (90% upper confidence bound
of 4.98%).
The absence of detectable PU.1 mutations in ALL patients is in
contrast to the results of our previous report where we detected
mutations in a large series of AML patients (Mueller et al, 2002). In
nine of 126 AML patients (7%), mutations of the PU.1 gene were
identified, with seven of these nine AML patients having
heterozygous mutations and two having both alleles affected by
different mutations. Seven of the PU.1 mutations in AML patients
affected the DNA-binding domain, and we demonstrated that those
PU.1 mutations were deficient in DNA binding to and transactiva-
tion of the macrophage colony-stimulating factor receptor
promoter, a direct PU.1 target gene. In addition, these mutations
decreased the ability of PU.1 to synergise with interacting proteins
such as AML1 or c-Jun to activate PU.1 target genes. Finally, some
of these mutations have lost the ability of the PU.1 wild-type
protein to induce terminal differentiation of PU.1-deficient
progenitor cells.
Our results suggest that, unlike in AML, PU.1 is not inactivated
by mutations in patients with ALL. Assuming a frequency of
mutational events similar to that seen in AML patients (7%), we
would expect to detect 4.34 mutations among the 62 ALL patients
screened. Because the number of patients of each ALL subtype in
our series is limited, we cannot exclude a low incidence of
mutations in some specific subtypes of ALL. In addition, because
we used exon-specific primers and DNA as a template, we cannot
rule out the presence of some mutations not detectable by this PCR
approach, for example, heterozygous deletions spanning one or
several exons.
The apparent absence of PU.1 mutations in ALL in contrast to
the presence of PU.1 mutations in some AML patients could be
linked with the function of the PU.1 protein. It was recently
hypothesised that differing concentrations of the PU.1 protein
regulate the development of B-lymphocytes as compared with
macrophages (DeKoter and Singh, 2000): A low concentration of
PU.1 protein (one-fifth to one-seventh as much) was proposed to
induce a B-cell fate, whereas a high concentration would promote
macrophage differentiation and block B-cell development. It is
noteworthy that wild-type macrophages express higher levels of
PU.1 protein than their pro-B counterparts (Chen et al, 1995). This
suggests that absence or reduction in the amount of wild-type PU.1
protein might have different consequences for myeloid and
lymphoid development. Whereas PU.1 mutations might contribute
to the malignant phenotype in myeloid cells, a mutant PU.1
peptide in lymphoid cells might lack consequences in terms of
leukaemogenesis.
ACKNOWLEDGEMENTS
This work was supported by grants from the Swiss National
Science Foundation SF 3100A0-100445 to BUM and SF 310000-
109388 to TP.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Chen HM, Zhang P, Voso MT, Hohaus S, Gonzalez DA, Glass CK, Zhang
DE, Tenen DG (1995) Neutrophils and monocytes express high levels of
PU.1 (Spi-1) but not Spi-B. Blood 85: 2918–2928
DeKoter RP, Singh H (2000) Regulation of B lymphocyte and
macrophage development by graded expression of PU.1. Science 288:
1439–1441
Table 1 Clinical characteristics of patients studied
(n)
Protocol
85-001 22
87-001 24
LALA 94 16
Age
Range (years) 1–62
Younger than 20 years 46
20 years or older 16
Immunophenotype
B-cell 62
T-cell 0
CNS involvement
No 57
Yes 5
Sex
Male 40
Female 22
WBC
o20000/ml2 7
420000/ml3 5
Cytogenetics
t(12;21) 11
t(9;22) 5
t(4;11) 2
t(1;19) 1
Complex 11
Normal 15
Others 13
NA 4
CNS¼central nervous system; NA¼not available; WBC¼white blood cell count.
Clinical characteristics at the time of diagnosis of the 62 ALL patients are shown.
Patients were enrolled on one of two consecutive Dana Farber Cancer Institute
childhood ALL protocols (85-001 and 87-001) or on the French Intergroup LALA 94
protocol for adult ALL patients.
Lack of PU.1 mutations in ALL
BU Mueller et al
1919
British Journal of Cancer (2006) 94(12), 1918–1920 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sFisher RC, Olson MC, Pongubala JM, Perkel JM, Atchinson ML, Scott EW,
Simon MC (1998) Normal myeloid development requires both the
glutamine-rich transactivation domain and the PEST region of
transcription factor PU.1 but not the potent acidic transactivation
domain. Mol Cell Biol 18: 4347–4357
Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG (1995)
PU.1 (Spi-1) and C/EBPa regulate the expression of the granulocyte–
macrophage colony-stimuating factor receptor a gene. Mol Cell Biol 15:
5830–5845
Hromas R, Orazi A, Neiman RS, Maki R, Van Beveran C, Moore J, Klemsz
M (1993) Hematopoietic lineage-restricted and stage-restricted expres-
sion of the ETS oncogene family member PU.1. Blood 82: 2998–3004
Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA (1990) The
macrophage and B cell-specific transcription factor PU.1 is related to the
ets oncogene. Cell 61: 113–124
McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault
H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, Maki RA (1996) Targeted
disruption of the PU.1 gene results in multiple hematopoietic
abnormalities. EMBO J 15: 5647–5658
McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J,
Koeffler HP, Takeuchi S, Janssen JW, Seriu T, Bartram CR, Sallan SE,
Gilliland DG, Golub TR (1996) TEL/AML1 dimerizes and is associated
with a favorable outcome in childhood acute lymphoblastic leukemia.
Blood 86: 4252–4258
Moreau-Gachelin F, Tavitian A, Tambourin P (1988) Spi-1 is a putative
oncogene in virally induced murine erythroleukaemias. Nature 331:
277–280
Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G,
Briand P, Vainchenker W, Tavitian A (1996) Spi-1/PU.1 transgenic mice
develop multistep erythroleukemias. Mol Cell Biol 16: 2453–2463
Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U,
Tenen DG (2006) ATRA resolves the differentiation block in t(15;17)
acute myeloid leukemia by restoring PU.1 expression. Blood 107:
3330–3338
Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G,
Hiddemann W, Ito Y, Tenen DG (2002) Heterozygous PU.1 mutations
are associated with acute myeloid leukemia. Blood 100: 998–1007
Paul R, Schuetze S, Kozak SL, Kozak CA, Kabat D (1991) The Sfpi-1
proviral integration site of Friend erythroleukemia encodes the ets-
related transcription factor PU.1. J Virol 65: 464–467
Rosenbauer F, Wagner K, Kutok JL, Iwasaki H, Le Beau MM, Okuno Y,
Akashi K, Fiering S, Tenen DG (2004) Acute myeloid leukemia induced
by graded reduction of a lineage-specific transcription factor, PU.1. Nat
Genet 36: 624–630
Scott EW, Simon MC, Anastai J, Singh H (1994) The transcription factor
PU.1 is required for the development of multiple hematopoietic lineages.
Science 265: 1573–1577
Shin MK, Koshland ME (1993) Ets-related protein PU.1 regulates
expression of the immunoglobulin J-chain gene through a novel Ets-
binding element. Genes Dev 7: 2006–2015
Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG (1996) PU.1
(Spi-1) and C/EBPa regulate the granulocyte colony-stimulating factor
receptor promoter in myeloid cells. Blood 88: 1234–1247
Voso MT, Burn TC, Wulf G, Lim B, Leone G, Tenen DG (1994) Inhibition of
hematopoiesis by competitive binding of the transcription factor PU.1.
Proc Natl Acad Sci USA 91: 7932–7936
Zhang DE, Hetherington CJ, Chen HM, Tenen DG (1994) The macrophage
transcription factor PU.1 directs tissue specific expression of
the macrophage colony stimulating factor receptor. Mol Cell Biol 14:
373–381
Lack of PU.1 mutations in ALL
BU Mueller et al
1920
British Journal of Cancer (2006) 94(12), 1918–1920 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s